Strategic Thrusts Banner
Engineering CELLS,
   Engineering RESPONSES
09
Oct 2019

Bioelectricity's promise for therapeutic targets in cancer, Phys Org

Bioelectricity of Cancer, a special issue of the peer-reviewed journal Bioelectricity, has just been published. A study by the Lee Kong Chian School of Medicine, the Nanyang Technological University, the Agency for Science Technology and Research (A*STAR), and the University of California, titled "Extracellular K+ Dampens T-Cell Functions: Implications for Immune Suppression in the Tumor Microenvironment”, was also published in the journal. This study demonstrated that the high K+, taken up by the anti-tumor T-cells (lymphocytes), significantly inhibited their proliferation as well as their production of cytokines whilst up-regulating the expression of the immune checkpoint protein PD-1.

19
Sep 2019

Blood test for stomach cancer first step to ending all cancer deaths by 2048, says its Singapore-based co-inventor, Business Insider India

MiRXES, a biotech company behind the GastroClear test, aims to boost patients’ prognosis for survival while reducing the health care burden of treating the disease. Company co-founders, Dr Zhou Lihan, Too Heng-Phon and Dr Zou Ruiyang, developed technology that could accurately detect microRNAs – ribonucleic acids found in plant and animal cells. The three were previously working in A*STAR and started their company in 2014.

18
Sep 2019

Blood test for stomach cancer first step to ending all cancer deaths by 2048, says its Singapore-based co-inventor, South China Morning Post Online

MiRXES, a biotech company behind the GastroClear test, aims to boost patients’ prognosis for survival while reducing the health care burden of treating the disease. Company co-founders, Dr Zhou Lihan, Too Heng-Phon and Dr Zou Ruiyang, developed technology that could accurately detect microRNAs – ribonucleic acids found in plant and animal cells. The three were previously working in A*STAR and started their company in 2014.

16
Aug 2019

How consumers' food preferences are changing, CNBC

CNBC's Oriel Morrison speaks to scientists and restaurant owners about the future of food and the business opportunities that lie ahead. Concerns over climate change and animal welfare are driving companies to explore alternatives to meat production such as cultured meat or plant-based products. The Agency for Science Technology and Research (A*STAR) is running trials on producing cleaner meat with a low carbon footprint, without the need to kill animals. Dr Kelvin Ng from A*STAR’s Bioprocessing Technology Institute (BTI) shared that once this concept reaches consumers’ minds, scientists can educate the public on why producing cultured meat is a different version of producing cells in the body. It is a more controlled version of producing meat with very similar nutritional benefits.

31
May 2019

Frontline: Interview with Prof Lam Kong Peng, ED of BTI on cultured meat, Channel 8

More than 50 F&B businesses are selling plant-based meat burgers from Impossible Foods since its venture into the Singapore market in March. In addition to plant-based meat, there are institutions here, such as A*STAR’s Bioprocessing Technology Institute, researching on cultured meat from animal cells. Professor Lam Kong Peng, Executive Director of BTI said cultured meat would be cleaner, have relatively stable nutrients, and have more customisable flavours. He expects cultured chicken meat is expected to be available in two to three years’ time.

29
May 2019

Study finds new way to starve cancer cells, The Straits Times

Researchers from A*STAR and the National Cancer Centre Singapore (NCCS) discovered that cancer stem cells can use an amino acid called methionine as fuel and are especially dependent on it. The team found that starving lung cancer cells of methionine for 48 hours resulted in a “dramatic” 94 per cent reduction in tumour size compared with a control sample. Dr Tam Wai Leong, Group Leader for Precision Oncology at the Genome Institute of Singapore under A*STAR, said that it may be possible to prevent the cancer stem cells from using methionine by inhibiting an enzyme called MAT2A, and that it will be important for clinicians to select patients who are most likely to benefit from such a drug. The study also involved researchers from A*STAR’s Bioprocessing Technology Institute (BTI) and the team is working on developing a drug for clinical trials that inhibits MAT2A.

29
May 2019

European Medicines Agency grants Marketing Authorisation Application for Prestige BioPharma's Herceptin biosimilar, BioSpectrum Asia

The Marketing Authorisation Application (MAA) for Prestige BioPharma's trastuzumab (Herceptin) biosimilar ̶ Tuznue/HD201 ̶ has been accepted for review by the European Medicines Agency (EMA). This brings Prestige's lead development candidate one step closer to being indicated for the treatment of adult patients with HER2-overexpressing breast, gastric, and gastroesophageal cancers. This review would put Tuznue in the race along with other biosimilars to seize the EU market, which is currently dominated by Herceptin. This acceptance was also recently boosted by the announcement of positive top-line results from a Phase III global clinical trial (Troika) of Tuznue, demonstrating its exceptional similarity to Herceptin in terms of clinical response, pharmacokinetics, and safety profile. Prestige BioPharma is a Singapore-based biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics. Its R&D laboratory is situated in the Bioprocessing Technology Institute (BTI), A*STAR.

28
May 2019

How Bacteria Influence Host Immunity, Science & Technology Research News

Researchers from A*STAR’s Institute of Molecular and Cell Biology (IMCB), Bioprocessing Technology Institute (BTI) and Singapore Immunology Network (SIgN) in collaboration with colleagues in China and Netherlands have sought to understand the influence that bacteria exert on the overall, or systemic, immune response of the body. They homed in on the molecule peptidoglycan (PGN), a major component of the bacterial cell wall. They observed that microbiota-colonised mice had significantly higher PGN levels compared to antibiotic-treated and germ-free mice.

27
May 2019

Local researchers found the source of nutrients for cancer cells, Lianhe Zaobao

我国跨机构科研人员成功破解癌症“始作俑者”的营养来源,日后若研发出能阻断癌细胞如何“消化”这个营养的新药,有望对付目前传统化疗无法治愈的癌症。 找出这个对抗癌症关键环节的是一组来自新加坡科技研究局属下两个研究院--新加坡基因研究院和生物处理科技研究院的科研人员,以及来自新加坡国立癌症中心的肿瘤学家。

27
May 2019

A Nutrition Pathway to Stamp out the Start of Cancer, Bio Spectrum

In a landmark study, scientists at the Agency of Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS), Bioprocessing Technology Institute (BTI) and oncologists at the National Cancer Centre Singapore (NCCC), have discovered that cancer stem cells, the founder cells of a tumour, have unique nutrient requirements. Unlike the rest of the tumour cells, cancer stem cells are addicted to a type of dietary amino acid -methionine- which is linked to its ability to form a tumour. The breakthrough innovation was announced by Dr Daniel S.W. Tan, Senior Clinician-Scientist, GIS and Dr Tam Wai Leong, Group leader, Precision Oncology, GIS on 27th May 2019 at A*STAR in Singapore.

14
May 2019

Interview with Prof Lam Kong Peng, Executive Director of BTI on cultured meat, Channel 8

Professor Lam Kong Peng, Executive Director of A*STAR’s Bioprocessing Technology Institute (BTI) shared about the process of culturing meat, which will be grown in large scale bioreactors. Regarding the nutritional value and safety of cultured meat, he said that meat cells should provide the same nutritional content as conventional meat and to ensure healthy cell growth, the bioreactor must be monitored stringently for contamination. BTI started culturing chicken cells due to the availability of chicken farms in Singapore and their next goal will be beef, pork, duck and seafood.

12
May 2019

Journey of local seafood from lab to farm to table, The Sunday Times

Singapore is taking various steps in order to become more self-sufficient in food production. For instance, A*STAR's Bioprocessing Technology Institute (BTI) has started trials on culturing meat, which will be grown on a large scale in bioreactors. Three technical groups comprising 10 scientists each have been formed to look at feed nutrition, disease and husbandry, as well as genetics and breeding.

06
May 2019

From lab to table, The Edge Singapore

Singapore is set to accelerate the growth of cultured meat research, led by the Agency for Science, Technology and Research (A*STAR) and its three-decade expertise in bioprocessing technology. Dr Kelvin Ng, head of strategic innovation at A*STAR’s Bioprocessing Technology Institute (BTI) shared that the proponents of these meat-replacement products assert that the alternatives are even better than the original. For one, lab-grown meats are just like genuine meat since they are grown from stem cells and A*STAR is researching alternatives to pharmaceutical-grade nutrient mixes amid the advances in global technology.

21
Apr 2019

Singapore increases efforts in producing food, Berita Minggu

As a small country with limited land area, Singapore needs to depend on a variety of foreign sources for its food supply. In fact, the country imports more than 90 percent of its food supplies from abroad. According to statistics from the Food and Agriculture Authority (AVA), only 9 percent of fish eaten in Singapore last year was produced in local livestock. In addition, A*STAR's Bioprocess Technology Institute (BTI) is utilising technology in bio-producers and bio-engineering to produce meat in the lab.

18
Apr 2019

Lab-grown and plant-based meat can help us move towards a more sustainable food system, TODAY Online

With the March launch of Impossible Foods’ plant-based meat in Singapore and this month’s announcement of S$144 million research funding in food innovation under the Government's Research, Innovation and Enterprise 2020 plan, Singapore has further established itself as a leader in shaping the food system of the future. This new research plan includes funding for cell-based meat, also known as clean meat, and is in line with Singapore’s previous investments in alternative proteins. Meanwhile, Dr Kelvin Ng, head of strategic innovation at A*STAR’s Bioprocessing Technology Institute (BTI) which has started trials on producing clean meat, had told Straits Times in a recent interview that clean meat will be cost-competitive with grass-fed meats within the next three to five years, compete with all meat products in about a decade, and eventually become less expensive than conventionally-produced meats.

29
Mar 2019

Singapore backs lab-grown meat under billion dollar innovation programme, Berita Harian Online

Cultured meat is a key protein alternative of the future and could be making its way to dinner plates here, as Singapore ramps up production of home-grown food. To make meat, stem cells extracted from chickens, cows, fish and pigs will be grown and multiplied in bioreactors, and eventually undergo tissue engineering to make whole meat cuts, say researchers. Singapore's Bioprocessing Technology Institute (BTI) has already started trials on culturing meat, which will be grown in bioreactors. Cells will comprise most of the culture meat, with bulking agents making up the rest. However, its nutritional value will be similar to traditional meat, according to Dr Kelvin Ng, the head of strategic innovation at BTI.

29
Mar 2019

Singapore backs lab-grown meat under billion dollar innovation programme, Just-Food

Cultured meat is a key protein alternative of the future and could be making its way to dinner plates here, as Singapore ramps up production of home-grown food. To make meat, stem cells extracted from chickens, cows, fish and pigs will be grown and multiplied in bioreactors, and eventually undergo tissue engineering to make whole meat cuts, say researchers. Singapore's Bioprocessing Technology Institute (BTI) has already started trials on culturing meat, which will be grown in bioreactors. Cells will comprise most of the culture meat, with bulking agents making up the rest. However, its nutritional value will be similar to traditional meat, according to Dr Kelvin Ng, the head of strategic innovation at BTI.

28
Mar 2019

Lab-grown meat getting boost from Government, The New Paper Online

Lab-grown meat is a key protein alternative of the future and could be making its way to dinner plates here, as Singapore ramps up production of home-grown food. The effort is getting a boost from the Government's Research, Innovation and Enterprise 2020 plan, under which $144 million is going into food-related research, including sustainable urban food production, future foods and food safety science and innovation. To make meat, stem cells extracted from chickens, cows, fish and pigs will be grown and multiplied in bioreactors, and eventually undergo tissue engineering to make whole meat cuts, said researchers.

28
Mar 2019

Using live chicken cells to cultivate chicken meat food products, Lianhe Wanbao

Cultured meat is a key protein alternative of the future and could be making its way to dinner plates here, as Singapore ramps up production of home-grown food. To make meat, stem cells extracted from chickens, cows, fish and pigs will be grown and multiplied in bioreactors, and eventually undergo tissue engineering to make whole meat cuts, say researchers. Leveraging its existing technology in bioproduction and stem cell bioengineering, A*STAR's Bioprocessing Technology Institute (BTI) has started trials on culturing meat, which will be grown in large scale bioreactors. Eventually, for both cultured meat cuts and minced meat, the cells will comprise only 20 to 50 per cent of the meat, but its nutritional value will be similar to that of traditional meat, said Dr Kelvin Ng, Head of Strategic Innovation at BTI.

28
Mar 2019

Beefing up efforts to grow meat in labs, The Straits Times

Cultured meat is a key protein alternative of the future and could be making its way to dinner plates here, as Singapore ramps up production of home-grown food. The effort is getting a boost from the Government's Research, Innovation and Enterprise 2020 plan, under which $144 million is going into food-related research, including sustainable urban food production, future foods and food safety science and innovation. To make meat, stem cells extracted from chickens, cows, fish and pigs will be grown and multiplied in bioreactors, and eventually undergo tissue engineering to make whole meat cuts, say A*STAR researchers.

19
Feb 2019

Tapeworm Drug Could Be an Effective Treatment for Certain Cancers, Bio Space

Scientists from A*STAR’s Institute of Molecular and Cell Biology (IMCB) have discovered that niclosamide, an FDA-approved anti-parasitic drug, can effectively kill p53-defective cancer cells, potentially increasing the specificity for cancer targeting and sparing normal cells that carry wildtype p53. The p53 gene is a tumour suppressor gene that inhibits the growth of tumours, and if this gene is mutated, cancer cells are able to thrive. Working in collaboration with researchers from A*STAR’s Bioprocessing Technology Institute (BTI) and p53 Laboratory, the Skin Research Institute of Singapore, Duke-NUS Medical School, the Cancer Science Institute of Singapore, KK Women’s and Children’s Hospital, National Cancer Centre Singapore, and National University of Singapore, the IMCB research team found that niclosamide, a drug conventionally used in the treatment of intestinal tapeworm infections, induces metabolic stress in colon cancer cells without p53, thereby effectively causing death of these cancer cells.

15
Feb 2019

Singapore researchers reveal role of anti-parasitic drug in treating cancer, Bio Spectrum

Scientists from A*STAR’s Institute of Molecular and Cell Biology (IMCB) have discovered that niclosamide, an FDA-approved anti-parasitic drug, can effectively kill p53-defective cancer cells, potentially increasing the specificity for cancer targeting and sparing normal cells that carry wildtype p53. The p53 gene is a tumour suppressor gene that inhibits the growth of tumours, and if this gene is mutated, cancer cells are able to thrive. Working in collaboration with researchers from A*STAR’s Bioprocessing Technology Institute (BTI) and p53 Laboratory, the Skin Research Institute of Singapore, Duke-NUS Medical School, the Cancer Science Institute of Singapore, KK Women’s and Children’s Hospital, National Cancer Centre Singapore, and National University of Singapore, the IMCB research team found that niclosamide, a drug conventionally used in the treatment of intestinal tapeworm infections, induces metabolic stress in colon cancer cells without p53, thereby effectively causing death of these cancer cells.

30
Jan 2019

Esco Aster, A*STAR to advance BioProcessing technologies for cell and gene therapies, Bio Spectrum Asia

Esco Aster, a contract development and manufacturing organisation (CDMO) of Esco Group, has announced the official opening of the BTI–ESCO ASTER Centre of Excellence in Bioprocessing in Biopolis, Singapore. The company has entered into an agreement with A*STAR’s Bioprocessing Technology Institute (BTI) to adopt an Industry 4.0 integrated bioprocessing platform. This COE marks a significant milestone to advance the development of safe and effective cell and gene therapies. Prof. Lam Kong-Peng, Executive Director of A*STAR’s Bioprocessing Technology Institute (BTI) said that BTI is pleased to be a partner in setting up this Centre of Excellence. It will leverage BTI’s expertise in bioprocessing science and engineering and affirms our commitment to work with local enterprises to develop innovative biomanufacturing solutions and meet the demands of the high-value cell and gene therapy space.

21
Jan 2019

New Stem Cell Antibody Targets Cancer, Science & Technology Research News

Researchers from A*STAR’s Bioprocessing Technology Institute (BTI) have developed an antibody that targets and is taken up only by certain types of cancer cells. Combining this antibody with an anticancer drug could lead to a new treatment for some types of breast and ovarian cancers. The team wanted to develop monoclonal antibodies that could specifically target and kill cancer cells through one of a variety of potential mechanisms. Pluripotent stem cells and many cancer cells share some of the same proteins, called oncofetal antigens, on their surfaces. They utilised this to develop monoclonal antibodies by injecting human embryonic stem cells (hESCs) into mice, spurring their immune system into producing antibodies.

21
Jan 2019

Making Heart Tissue ‘Beat’, Science & Technology Research News

Researchers from A*STAR’s Bioprocessing Technology Institute (BTI) have shown that the key to efficient cardiac cell production lies in syncing the induction of differentiation with the cell cycle of the starting pluripotent material. Although a widely used protocol for making heart muscle seems to work better with some stem cell lines than others, the team found this same standard method can be made to work with all stem cells with high efficiency if the cells are first cultured at optimal densities and stages of the cell cycle ahead of cardiac induction.

15
Jan 2019

Antibody that targets a protein on the surface of stem cells also targets same protein on cancer cells, Medical Xpress

Researchers from A*STAR’s Bioprocessing Technology Institute (BTI) have developed an antibody that targets and is taken up only by certain types of cancer cells. Combining this antibody with an anticancer drug could lead to a new treatment for some types of breast and ovarian cancers. The team wanted to develop monoclonal antibodies that could specifically target and kill cancer cells through one of a variety of potential mechanisms. Pluripotent stem cells and many cancer cells share some of the same proteins, called oncofetal antigens, on their surfaces. They utilised this to develop monoclonal antibodies by injecting human embryonic stem cells (hESCs) into mice, spurring their immune system into producing antibodies.

15
Jan 2019

Researchers report key to efficient production of heart muscle from pluripotent stem cells, Medical Xpress

Researchers from A*STAR’s Bioprocessing Technology Institute (BTI) have shown that the key to efficient cardiac cell production lies in syncing the induction of differentiation with the cell cycle of the starting pluripotent material. Although a widely used protocol for making heart muscle seems to work better with some stem cell lines than others, the team found this same standard method can be made to work with all stem cells with high efficiency if the cells are first cultured at optimal densities and stages of the cell cycle ahead of cardiac induction.

03
Jan 2019

Unlocking New Antibiotics, Science & Technology Research News

A*STAR researchers from ICES, BTI, MERL and MEL have unearthed a new antibiotic, auroramycin, from a silent biosynthetic gene cluster discovered in the S. roseosporus genome, and believe there are many more just waiting to be found. Dr Yee Hwee Lim from ICES said that this strain of bacteria is very well studied and it was interesting that, even after so many molecules have been discovered, they now have a new antibiotic simply because they had the tools to access it. The team used CRISPR-Cas9 to introduce a potent gene transcription activator - the kasO* promoter - into the bacterial genome to activate expression of an entire cryptic biosynthetic gene cluster. The gene cluster was found to encode auroramycin, an antibiotic with potent antibacterial activity against Gram-positive bacteria, including MRSA and vancomycin-resistant Enterococcus faecalis (VRE).

03
Jan 2019

Uncapping a New Therapy, Science & Technology Research News

Scientists from A*STAR have found that switching off the enzyme that adds protective caps to chromosome ends could help fight many types of cancer. The team from GIS, IMB, IMCB and BTI demonstrated the treatment's potential by using it to thwart tumour growth in mice. The team found that a master regulator of development, HOXC5, and the microRNA mir-615-3p, which is nested inside the HOXC5 gene, act together to suppress telomerase through these distant switches. Further study showed that the switches are present in many long-lived mammals, including humans and chimpanzees, but not in short-lived mammals, like mice and rats, as an extra barrier against the increased tumour risk that accompanies a longer lifespan.

06
Dec 2018

Cancer Early Detection Firm Ark Launches With $40M Series A Investment, Genome Web

Singapore-based cancer detection firm Ark said today that it has raised $40 million in a Series A investment led by shareholders of Venturecraft and backed by Gaorong Capital (formerly Banyan Capital). The company is the result of a merger between Venturecraft and MiRxes, a technology firm that was spun out of the Agency for Science, Technology and Research (A*STAR) in 2014. Ark's mission is to develop early cancer detection tests across different tumor types, but its first product is a more focused blood test for the detection of early-stage stomach cancer in asymptomatic individuals.

04
Dec 2018

Blood Factories Closer to Reality, Science & Technology Research News

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have optimized the molecular recipes and growth-supporting microparticles needed to prepare and sustain billions of stem cell-derived red blood cells (RBCs) in industrial-scale manufacturing vessels known as bioreactors. They have shown that transient activation of a key signaling pathway can dramatically boost efficiencies across a range of starting materials. The system is still nowhere near producing the 1–2 trillion RBCs found in each 'unit' of donated blood - but it's getting close. And soon, Jaichandran Sivalingam, a research scientist at BTI, expects the platform to help solve the dual problem of supply shortages and transmissible infections that undermine transfusion medicine.

30
Nov 2018

Blood factories closer to reality, Medical Xpress

Scientists from A*STAR’s Bioprocessing Technology Institute (BTI) have optimized the molecular recipes and growth-supporting microparticles needed to prepare and sustain billions of stem cell-derived red blood cells (RBCs) in industrial-scale manufacturing vessels known as bioreactors. They have shown that transient activation of a key signaling pathway can dramatically boost efficiencies across a range of starting materials. The system is still nowhere near producing the 1–2 trillion RBCs found in each 'unit' of donated blood - but it's getting close. And soon, Jaichandran Sivalingam, a research scientist at BTI, expects the platform to help solve the dual problem of supply shortages and transmissible infections that undermine transfusion medicine.

27
Nov 2018

Medtech firm Ark Bio launched with US$40m Series A funding, The Business Times

Singapore's Venturecraft has merged with medtech startup Mirxes to form Ark Bio, a cancer detection company armed with a US$40 million Series A investment. The early-stage cancer detection test was developed by Mirxes, which was spun off from A*STAR in 2014. Under the merger, both Mirxes and Venturecraft became wholly owned subsidiaries of Ark. Ark’s first product will be a stomach cancer blood test which detects early-stage stomach cancer before clinical symptoms appear. It was developed and validated in collaboration with the Singapore Gastric Cancer Consortium, A*STAR’s Diagnostics Development Hub (DxD Hub), the National University Hospital and Tan Tock Seng Hospital.

27
Nov 2018

Singapore team gets funding to ‘eliminate late-stage cancer’, Tech In Asia

Local biomedical startup Ark has secured US$40 million in funding ahead of the early 2019 rollout of its first non-invasive, blood-based cancer test kit, which is focused on gastric cancer. Co-CEO Dr. Zhou Lihan said that working in Singapore’s prestigious Agency for Science, Technology, and Research (A*STAR), before striking out on his own, meant that he and his team received valuable support and education on how to commercialise technology. As a scientist, Zhou acknowledged that he initially felt “out of his comfort zone” leaping into the business world, and that the past few years of being at the helm of a stealth startup had been a pretty steep learning curve, but A*STAR had helped considerably in the team’s commercialization journey.

20
Sep 2018

Stars in the spotlight, The Straits Times

On its 10th anniversary, past winners of President’s Science and Technology Awards (PSTA) talk about their inspiration and how Singapore’s investment in research and development has borne fruit. A*STAR’s Chairman Mr Lim Chuan Poh says that the PSTA reflects the meaningful contributions of Singapore’s scientific talents and gives glimpse of the diverse fields and capabilities across our public research institutes, institutes of higher learning, as well as the hospitals and clinical community. Since its inception, a total of 34 awards have been conferred at PSTA on individuals and team for their outstanding and invaluable contributions to the research and development landscape in Singapore.

07
Sep 2018

10 Things you should know about the Singapore startup landscape, Yahoo! Online

With Singapore Week of Innovation and TeCHnology (SWITCH) just around the corner, there is a significant interest directed at Singapore these days. Singapore’s tech and startup scene attracts much interests, especially when the city-state became the only Southeast Asian country to rank in Startup Genome’s Top 20 Startup Ecosystems in World report in 2015. There is an increasing number of deals and VC investment amounts in deep tech. As showcased in SLINGSHOT, the Singapore government focusses on attracting and building more startups in deep tech sectors like medtech, cleantech, fintech, and future mobility, among others. These are also in line with the global trends – increased focus on Industry 4.0, increasing emphasis on healthcare due to an ageing population, as well as rapid urbanisation and digitalisation, particularly in Asia. One such example is MiRXES, a spin off from A*STAR’s Bioprocessing Technology Institute (BTI). The startup has developed an alternative non-invasive solution to accurately diagnose cancer through blood tests, at an earlier stage and with a higher degree of accuracy. MiRXES has raised about US$2.9 million in Series A.

09
Aug 2018

National Day Award 2018, The Straits Times

Dr Benjamin Seet Hun Yew, Executive Director, A*STAR’s Biomedical Research Council received The Public Administration Medal (Silver); Dr Andre Choo Boon Hwa Institute Scientist, A*STAR’s Bioprocessing Technology Institute received The Public Administration Medal (Bronze); and Ms Khadijah Abdul Rahman, Head of Finance at A*STAR received The Commendation Medal.

28
Jun 2018

Promising biomedical start-ups in Singapore, Straits Times Online

The Straits Times lists startups that have promise in biomedical field. One of them is Biotech company MiRXES, co-founded by Associate Professor Too Heng-Phon and Dr Zhou Lihan, has developed technology kits that can detect early-stage gastric cancer, breast cancer and lung cancer from blood samples. Another one is Immunoscape which has come up with a technique to create maps of T-cells, which help to regulate the body's immune response to diseases. There are millions of such cells, which can kill tumours or viruses.

30
Oct 2017

Roquette Opens Innovation Centre In Singapore, Asia Pacific Food Industry

French plant-based ingredients maker Roquette opened its regional headquarters and a innovation centre in Singapore as it steps up its focus on Asian growth. Roquette said its over 1,100 sqm new innovation centre at Biopolis will allow the company to partner with customers, universities and research institutions, such as Singapore's Agency for Science, Technology and Research (A*STAR) or the National University of Singapore. A*STAR chairman Lim Chuan Poh who was guest of honour at the opening, noted that Singapore is home to the R&D centres of some of the world's largest food, nutrition and pharmaceutical companies like Nestle. Mr Lim also announced tie-ups between Roquette and A*STAR's Bioprocessing Technology Institute (BTI) and Clinical Nutrition Research Centre (CNRC) to look at issues such as how different Asian populations react to certain dietary ingredients.

27
Oct 2017

French MNC opens regional HQ in Singapore, The Straits Times

French plant-based ingredients maker Roquette opened its regional headquarters and innovation centre in Singapore as it steps up its focus on Asian growth. Roquette said its over 1,100 sqm new innovation centre at Biopolis will allow the company to partner with customers, universities and research institutions, such as Singapore's Agency for Science, Technology and Research (A*STAR) or the National University of Singapore. A*STAR chairman Lim Chuan Poh who was guest of honour at the opening, noted that Singapore is home to the R&D centres of some of the world's largest food, nutrition and pharmaceutical companies like Nestle. Mr Lim also announced tie-ups between Roquette and A*STAR's Bioprocessing Technology Institute (BTI) and Clinical Nutrition Research Centre (CNRC) to look at issues such as how different Asian populations react to certain dietary ingredients.

28
Jun 2017

Study Pinpoints Best Stage of Stem Cell Differentiation for Use in Treating Parkinson’s Disease, PR Webs

Studies indicate that replacing damaged brain cells with those derived from human embryonic stem cells might lead to an effective treatment for Parkinson’s disease. A new study coming out of Singapore, recently published in STEM CELLS Translational Medicine journal addresses the optimal stage that the transplantation of differentiation of stem cells should take place in order to gain the best results. The study is co-led by the National Neuroscience Institute, Singapore (NNI) and the Agency for Science, Technology and Research (A*STAR).

19
Apr 2017

Red blood cells derived from stem cells could offer a limitless supply for transfusions, Medical Xpress

Researchers from A*STAR's Bioprocessing Technology Institute (BTI) have grown red blood cells (RBCs) from stem cells in an efficient and reliable way. Lab-grown blood offers a potentially limitless solution, but existing methods for manufacturing blood from stem cells are not appropriate for clinical use. Jaichandran and his colleagues got around these problems by using tiny plastic spheres known as microcarriers. These spheres float in suspension, providing large amounts of surface area. And covering them in a human protein called laminin-521 eliminates the need for any animal material. By culturing the stem cells on these microcarriers and adjusting the media, the A*STAR team could generate at least six times as many RBC precursor cells and 80 times as many differentiated RBCs as the standard method involving embryoid bodies in a dish. Since reporting the method last year, the researchers have boosted the yields even further.

18
Apr 2017

Taking the sting out of bone repair, Science Daily

Researchers at A*STAR's Bioprocessing Technology Institute (BTI) and Institute of Materials Research and Engineering (IMRE) have developed small biodegradable and biocompatible supports that aid stem cell differentiation and multiplication as well as bone formation in living animal models. Existing approaches to expand stem cells for industrial applications tend to use two-dimensional materials as culture media, but their production yields are too low for clinical demand. Furthermore, stem cells typically need to be harvested with enzymes and attached to a scaffold before they can be implanted. To bring commercially viable cell therapies to market, Asha Shekaran and Steve Oh, from BTI, have created directly implantable microscopic spheres in collaboration with IMRE. These spheres, which acted as heMSC microcarriers, consist of a biodegradable and biocompatible polymer called polycaprolactone.

07
Apr 2017

Stem cells: Single-use bioreactors and microcarriers can overcome scale-up issues, experts, Bio Pharma

The only practical way to scale-up volumes of mesenchymal stem cells (MSCs) is by using microcarriers in single-use bioreactors, say scientists from A*STAR and Instituto Superior Técnico. Dr Steve Oh, principal scientist and associate director at A*STAR's Bioprocessing Technology Institute (BTI), said that a similar set-up had shown promise in moving MSC cultivation into scalable technologies and his team is trying to move to a 15L scale. However, the goal for MSC-based therapies would be producing commercial volumes of '10,000 doses per year, each of billion cells' from the onset.

17
Mar 2017

Waters Honours Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Labmate Online

17
Mar 2017

Waters Honours Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Labmate Online

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

08
Mar 2017

Waters Honors Singapore’s Bioprocessing Technology Institute for Glycoscience Research, Technology Networks

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

07
Mar 2017

Waters to chip in expertise for Singapore’s Bioprocessing Technology Institute in glycoscience research, Pharma Biz

Waters Corporation will be assisting A*STAR's Bioprocessing Technology Institute (BTI) in its glycoscience research. BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program. BTI’s glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies. According to Dr. Mike Harrington, senior vice president, global markets for Waters Corporation, BTI’s research in glycobiology is world-class and they wish to help it realize the enormous potential of this very important area of science through the application of Waters analytical technologies and expertise.

27
Feb 2017

A*STAR’s Bioprocessing Technology Institute recognised as the Centre of Innovation by Waters Corporation, A*STAR Website

A*STAR’s Bioprocessing Technology Institute (BTI) has been recognised by Waters Corporation as the Centre of Innovation on 27 Feb 2017. BTI is the first research institute focused on glycobiology to participate in Waters’ Centers of Innovation Program. Its glycan research is aimed at finding novel cancer markers and elucidating glycosylation pathways that could pave the way for new therapeutic strategies.

27
Feb 2017

Waters Honors Singapore’s Bioprocessing Technology Institute (BTI) for Glycoscience Research, Bloomberg

At a ceremony and symposium today, Waters Corporation (NYSE:WAT) welcomed into its Centers of Innovation Program the Bioprocessing Technology Institute (BTI), a research institute under Singapore’s Agency for Science, Technology and Research (A*STAR). BTI is the first research institute focused on glycobiology to participate in the Waters Centers of Innovation Program.

Page 1 of 5First   Previous   [1]  2  3  4  5  Next   Last